Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients

Background. Leuprolide, an agonist of luteinizing hormone‐releasing hormone (LH‐RH), and flutamide, an antiandrogen, increasingly are being used in the treatment of clinically localized prostate cancer. Only two small series (of 23 and 12 patients) have been published on the distinctive pathologic changes induced in the prostate by androgen deprivation therapy with discrepancies on the presence of squamous metaplasia, necrosis, and possible tumor destruction by combined androgen deprivation therapy.

[1]  M. Soloway,et al.  Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide. , 1995, Urology.

[2]  D. Bostwick,et al.  Neuroendocrine Differentiation in Prostatic Intraepithelial Neoplasia and Adenocarcinoma , 1994, The American journal of surgical pathology.

[3]  D. Bostwick,et al.  Decrease of prostatic intraepithelialneoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy , 1994 .

[4]  W. Murphy,et al.  Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone–‐releasing hormone effect). Distinction from poor tumor differentiation , 1994, Cancer.

[5]  M. Soloway,et al.  Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer. , 1994, Urology.

[6]  R. Thisted,et al.  Results of conservative management of clinically localized prostate cancer. , 1994, The New England journal of medicine.

[7]  E. Jones,et al.  The differential diagnosis of prostatic carcinoma. Its distinction from premalignant and pseudocarcinomatous lesions of the prostate gland. , 1994, American journal of clinical pathology.

[8]  M. Soloway,et al.  Bladder neck preservation and its impact on positive surgical margins during radical prostatectomy. , 1993, Urology.

[9]  D. Gleason,et al.  Histologic grading of prostate cancer: a perspective. , 1992, Human pathology.

[10]  T. Stamey,et al.  Mucinous differentiation in prostatic adenocarcinoma. , 1991, Human pathology.

[11]  M. Soloway,et al.  Pathologic changes associated with androgen deprivation therapy for prostate cancer , 1991, Cancer.

[12]  J. Srigley,et al.  Effect of Combination Endocrine Therapy (LHRH Agonist and Flutamide) on Normal Prostate and Prostatic Adenocarcinoma: A Histopathologic and Immunohistochemical Study , 1991, The American journal of surgical pathology.

[13]  N. Kyprianou,et al.  Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. , 1990, Cancer research.

[14]  N. Kyprianou,et al.  Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death , 1989 .

[15]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[16]  K. Gatter,et al.  KP1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. , 1989, Journal of clinical pathology.

[17]  N. Kyprianou,et al.  Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration , 1989, The Prostate.

[18]  F. Labrie,et al.  Treatment of prostate cancer with gonadotropin-releasing hormone agonists. , 1986, Endocrine reviews.

[19]  D. Bostwick,et al.  Intraductal dysplasia: a premalignant lesion of the prostate. , 1986, Human pathology.

[20]  R. Sharifi,et al.  Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. , 1985, Urology.

[21]  D. Grignon,et al.  Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy , 1985 .

[22]  B. Helpap.  Treated prostatic carcinoma. Histological, immunohistochemical and cell kinetic studies. , 1985, Applied pathology.

[23]  Soloway Ms.  Newer methods of hormonal therapy for prostate cancer. , 1984 .

[24]  D. Bostwick,et al.  Radiation injury of the normal and neoplastic prostate , 1982, The American journal of surgical pathology.

[25]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[26]  J. D. Fergusson,et al.  The response of prostatic carcinoma to œstrogen treatment , 1953, The British journal of surgery.